Dactolisib

Dactolisib (also known as BEZ235) is an experimental drug candidate for the treatment of various types of cancer. It is a dual PI3K inhibitor and mTOR inhibitor and has been shown to inhibit both phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) in preclinical studies.

Mechanism of Action

Dactolisib works by inhibiting the PI3K/AKT/mTOR pathway, which is often overactive in many types of cancer. This pathway is involved in cell growth, proliferation, and survival. By inhibiting this pathway, Dactolisib can potentially slow down or stop the growth of cancer cells.

Clinical Trials

Dactolisib has been tested in several clinical trials for various types of cancer, including breast cancer, lung cancer, and renal cell carcinoma. However, the results have been mixed, and further research is needed to determine the effectiveness and safety of this drug.

Side Effects

Like all drugs, Dactolisib can cause side effects. The most common side effects reported in clinical trials include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include hyperglycemia, pneumonitis, and rash.

Future Research

While Dactolisib has shown promise in preclinical studies and early-phase clinical trials, more research is needed to determine its effectiveness and safety in larger populations of patients. Future research may also explore the potential of Dactolisib in combination with other cancer treatments.

See Also

• PI3K inhibitor
• mTOR inhibitor
• Clinical trial
• Cancer

Dactolisib Resources
Latest articles Most recent articles Ongoing trials	Wikipedia